BACKGROUND AND OBJECTIVE: Narrow-spectrum antibiotics are recommended as the first-line agent for children hospitalized with community-acquired pneumonia (CAP). There is little scientific evidence to support that this consensus-based recommendation is as effective as the more commonly used broad-spectrum antibiotics. The objective was to compare the effectiveness of empiric treatment with narrow-spectrum therapy versus broad-spectrum therapy for children hospitalized with uncomplicated CAP. METHODS: This multicenter retrospective cohort study using medical records included children aged 2 months to 18 years at 4 children's hospitals in 2010 with a discharge diagnosis of CAP. Patients receiving either narrow-spectrum or broad-spectrum therapy in the first 2 days of hospitalization were eligible. Patients were matched by using propensity scores that determined each patient's likelihood of receiving empiric narrow or broad coverage. A multivariate logistic regression analysis evaluated the relationship between antibiotic and hospital length of stay (LOS), 7-day readmission, standardized daily costs, duration of fever, and duration of supplemental oxygen. RESULTS: Among 492 patients, 52% were empirically treated with a narrow-spectrum agent and 48% with a broad-spectrum agent. In the adjusted analysis, the narrow-spectrum group had a 10-hour shorter LOS (P = .04). There was no significant difference in duration of oxygen, duration of fever, or readmission. When modeled for LOS, there was no difference in average daily standardized cost (P = .62) or average daily standardized pharmacy cost (P = .26). CONCLUSIONS: Compared with broad-spectrum agents, narrow-spectrum antibiotic coverage is associated with similar outcomes. Our findings support national consensus recommendations for the use of narrow-spectrum antibiotics in children hospitalized with CAP.
BACKGROUND AND OBJECTIVE: Narrow-spectrum antibiotics are recommended as the first-line agent for children hospitalized with community-acquired pneumonia (CAP). There is little scientific evidence to support that this consensus-based recommendation is as effective as the more commonly used broad-spectrum antibiotics. The objective was to compare the effectiveness of empiric treatment with narrow-spectrum therapy versus broad-spectrum therapy for children hospitalized with uncomplicated CAP. METHODS: This multicenter retrospective cohort study using medical records included children aged 2 months to 18 years at 4 children's hospitals in 2010 with a discharge diagnosis of CAP. Patients receiving either narrow-spectrum or broad-spectrum therapy in the first 2 days of hospitalization were eligible. Patients were matched by using propensity scores that determined each patient's likelihood of receiving empiric narrow or broad coverage. A multivariate logistic regression analysis evaluated the relationship between antibiotic and hospital length of stay (LOS), 7-day readmission, standardized daily costs, duration of fever, and duration of supplemental oxygen. RESULTS: Among 492 patients, 52% were empirically treated with a narrow-spectrum agent and 48% with a broad-spectrum agent. In the adjusted analysis, the narrow-spectrum group had a 10-hour shorter LOS (P = .04). There was no significant difference in duration of oxygen, duration of fever, or readmission. When modeled for LOS, there was no difference in average daily standardized cost (P = .62) or average daily standardized pharmacy cost (P = .26). CONCLUSIONS: Compared with broad-spectrum agents, narrow-spectrum antibiotic coverage is associated with similar outcomes. Our findings support national consensus recommendations for the use of narrow-spectrum antibiotics in children hospitalized with CAP.
Authors: Sherry Weitzen; Kate L Lapane; Alicia Y Toledano; Anne L Hume; Vincent Mor Journal: Pharmacoepidemiol Drug Saf Date: 2004-12 Impact factor: 2.890
Authors: Timothy H Dellit; Robert C Owens; John E McGowan; Dale N Gerding; Robert A Weinstein; John P Burke; W Charles Huskins; David L Paterson; Neil O Fishman; Christopher F Carpenter; P J Brennan; Marianne Billeter; Thomas M Hooton Journal: Clin Infect Dis Date: 2006-12-13 Impact factor: 9.079
Authors: Anna K Weiss; Matthew Hall; Grace E Lee; Matthew P Kronman; Seth Sheffler-Collins; Samir S Shah Journal: Pediatrics Date: 2011-01-10 Impact factor: 7.124
Authors: Ross E Newman; Erin B Hedican; Joshua C Herigon; David D Williams; Arthur R Williams; Jason G Newland Journal: Pediatrics Date: 2012-02-20 Impact factor: 7.124
Authors: Adam L Hersh; Daniel J Shapiro; Jason G Newland; Philip M Polgreen; Susan E Beekmann; Samir S Shah Journal: PLoS One Date: 2011-05-31 Impact factor: 3.240
Authors: Derek J Williams; Matthew Hall; Jeffrey S Gerber; Mark I Neuman; Adam L Hersh; Thomas V Brogan; Kavita Parikh; Sanjay Mahant; Anne J Blaschke; Samir S Shah; Carlos G Grijalva Journal: Pediatrics Date: 2017-03-08 Impact factor: 7.124
Authors: Susan C Lipsett; Matthew Hall; Lilliam Ambroggio; Adam L Hersh; Samir S Shah; Thomas V Brogan; Jeffrey S Gerber; Derek J Williams; Carlos G Grijalva; Anne J Blaschke; Mark I Neuman Journal: J Pediatr Date: 2020-10-10 Impact factor: 4.406
Authors: Nicole M A Le Saux; Jennifer Bowes; Isabelle Viel-Thériault; Nisha Thampi; Julie Blackburn; Melanie Buba; Mary-Ann Harrison; Nick Barrowman Journal: Paediatr Child Health Date: 2020-06-30 Impact factor: 2.253